



# Source details

## Journal of Pharmacy and Pharmacognosy Research

Open Access ⓘ

Years currently covered by Scopus: from 2013 to 2025

Publisher: Asociacion Academica de Ciencias Farmaceuticas de Antofagasta (ASOCIFA)

E-ISSN: 0719-4250

Subject area: Health Professions: Pharmacy Medicine: Complementary and Alternative Medicine  
Pharmacology, Toxicology and Pharmaceutics: Pharmaceutical Science View all ✓

Source type: Journal

View all documents Set document alert  Save to source list

CiteScore CiteScore rank & trend Scopus content coverage

CiteScore 2024

3.2 =  $\frac{1,171 \text{ Citations } 2021 - 2024}{371 \text{ Documents } 2021 - 2024}$

Calculated on 05 May, 2025

CiteScoreTracker 2025 ⓘ

2.0 =  $\frac{823 \text{ Citations to date}}{404 \text{ Documents to date}}$

Last updated on 05 June, 2025 • Updated monthly

### CiteScore rank 2024 ⓘ

| Category                               | Rank    | Percentile |
|----------------------------------------|---------|------------|
| Health Professions                     |         |            |
| Pharmacy                               | #12/47  | 75th       |
| Medicine                               |         |            |
| Complementary and Alternative Medicine | #42/112 | 62nd       |

[View CiteScore methodology](#) [CiteScore FAQ](#) [Add CiteScore to your site](#)

CiteScore 2024 ⓘ  
3.2

SJR 2024 ⓘ  
0.314

SNIP 2024 ⓘ  
0.628

---

## About Scopus

[What is Scopus](#)

[Content coverage](#)

[Scopus blog](#)

[Scopus API](#)

[Privacy matters](#)

## Language

[日本語版を表示する](#)

[查看简体中文版本](#)

[查看繁體中文版本](#)

[Просмотр версии на русском языке](#)

## Customer Service

[Help](#)

[Tutorials](#)

[Contact us](#)

---

## ELSEVIER

[Terms and conditions](#) ↗ [Privacy policy](#) ↗ [Cookies settings](#)

All content on this site: Copyright © 2025 Elsevier B.V. ↗, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.

We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies ↗.



Journal of Pharmacy and Pharmacognosy Research

COUNTRY

Chile

Universities and research institutions in Chile

Media Ranking in Chile

SUBJECT AREA AND CATEGORY

Health Professions

Pharmacy

Medicine

Complementary and Alternative Medicine

Pharmacology, Toxicology and Pharmaceutics

Drug Discovery

Pharmaceutical Science

Pharmacology

PUBLISHER

Asociacion Academica de Ciencias

Farmaceuticas de Antofagasta (ASOCIFA)

SJR 2024

0.314 Q2

H-INDEX

21

PUBLICATION TYPE

Journals

ISSN

07194250

COVERAGE

2013-2025

INFORMATION

Homepage

How to publish in this journal

editor@jppres.com

SCOPE

The Journal of Pharmacy & Pharmacognosy Research (JPPRes) is an international, specialized and peer-reviewed open access journal, under the auspices of AVAGAX – Diseño, Publicidad y Servicios Informáticos, which publishes studies in the pharmaceutical and herbal fields concerned with the physical, botanical, chemical, biological, toxicological properties and clinical applications of molecular entities, active pharmaceutical ingredients, devices and delivery systems for drugs, vaccines and biologicals, including their design, manufacture, evaluation and marketing. This journal publishes research papers, reviews, commentaries and letters to the editor as well as special issues and review of pre-and post-graduate thesis from pharmacists or professionals involved in Pharmaceutical Sciences or Pharmacognosy.

Join the conversation about this journal

# Scopus indexed journal-Low APC

Quick and easy journal publication support. Publication in 30-45 Da


JAB Journal

0

## FIND SIMILAR JOURNALS

option:

|                                                                                              |                                                         |                                                                                |                                                                  |                                                                      |
|----------------------------------------------------------------------------------------------|---------------------------------------------------------|--------------------------------------------------------------------------------|------------------------------------------------------------------|----------------------------------------------------------------------|
| 1<br>Advances in Pharmacological and Pharmaceutical Sciences<br>GBR<br><br>70%<br>similarity | 2<br>Phytomedicine Plus<br>NLD<br><br>70%<br>similarity | 3<br>Journal of Applied Pharmaceutical Science<br>IND<br><br>67%<br>similarity | 4<br>Journal of Natural Remedies<br>IND<br><br>67%<br>similarity | 5<br>Journal of HerbMed Pharmacology<br>IRN<br><br>66%<br>similarity |
|----------------------------------------------------------------------------------------------|---------------------------------------------------------|--------------------------------------------------------------------------------|------------------------------------------------------------------|----------------------------------------------------------------------|



SCImago Graphica

Explore, visually communicate and make sense of data with our



Journal of Pharmacy and Pharmacognosy Research  
Q2  
Complementary and Alternative Medicine  
best quartile  
SJIR 2024  
0.31  
powered by scimagojr.com

Show this widget in your own website

Just copy the code below and paste within your html code:

<a href="https://www.scima

Ads by clickio

Already have a manuscript?

Use our Manuscript Matcher to find the best relevant journals!

Find a Match

## Refine Your Search Results

Journal of Pharmacy &amp; Pharmacognosy Research

Search

Sort By: Relevancy

## Filters

 Clear All

Web of Science Coverage

## Core Collection

- ☒ Science Citation Index Expanded (SCIE)
- ☒ Social Sciences Citation Index (SSCI)
- ☒ Arts & Humanities Citation Index (AHCI)
- ☒ Emerging Sources Citation Index (ESCI)

## Current Contents

- ☐ Agriculture, Biology & Environmental Sciences
- ☐ Arts & Humanities
- ☐ Business Collection
- ☐ Clinical Medicine
- ☐ Electronics & Telecommunications Collection
- ☐ Engineering, Computing & Technology
- ☐ Life Sciences
- ☐ Physical, Chemical & Earth Sciences
- ☐ Social And Behavioral Sciences

## Other

- ☐ BIOSIS
- ☐ Current Chemical Reactions
- ☐ Essential Science Indicators

## Active Filters

SCIENCE CITATION INDEX EXPANDED (SCIE) × SOCIAL SCIENCES CITATION INDEX (SSCI) ×  
ARTS & HUMANITIES CITATION INDEX (AHCI) × EMERGING SOURCES CITATION INDEX (ESCI) ×

## Search Results

Found 22,646 results (Page 1)

[Share These Results](#)

## Exact Match Found

## JOURNAL OF PHARMACY &amp; PHARMACOGNOSY RESEARCH

OPEN ACCESS

Publisher: JOURNAL PHARMACY &amp; PHARMACOGNOSY RESEARCH-JPPRES , ANGAMOS 0610, ANTOFAGASTA, CHILE, 00000

ISSN / eISSN: 0719-4250

Web of Science Core Collection: Emerging Sources Citation Index

[Share This Journal](#)[View profile page](#)

\* Requires free login.

## Other Possible Matches

## RESEARCH JOURNAL OF PHARMACOGNOSY

OPEN ACCESS

Publisher: IRANIAN SOC PHARMACOGNOSY , NO 8 SHAMS ALLEY, VALI-E-ASR ST, TEHRAN, IRAN, 00000

ISSN / eISSN: 2345-4458 / 2345-5977

Web of Science Core Collection: Emerging Sources Citation Index

[Share This Journal](#)[View profile page](#)

\* Requires free login.

## EXPLORATORY RESEARCH IN CLINICAL AND SOCIAL PHARMACY

OPEN ACCESS

Publisher: ELSEVIER , RADARWEG 29, AMSTERDAM, Netherlands, 1043 NX

ISSN / eISSN: 2667-2766

Web of Science Core Collection: Emerging Sources Citation Index

Additional Web of Science Indexes: Biological Abstracts | BIOSIS Previews

- ☐ Index Chemicus
- ☐ Zoological Record

Open Access 

Category

Country / Region

Language

Frequency

Journal Citation Reports

[Share This Journal](#)

[View profile page](#)

\* Requires free login.

## INTEGRATED PHARMACY RESEARCH AND PRACTICE

OPEN ACCESS

Publisher: DOVE MEDICAL PRESS LTD , PO BOX 300-008, ALBANY, NEW ZEALAND, AUCKLAND, 0752

ISSN / eISSN: 2230-5254

Web of Science Core Collection: Emerging Sources Citation Index

[Share This Journal](#)

[View profile page](#)

\* Requires free login.

## JOURNAL OF PHARMACY PRACTICE AND RESEARCH

Publisher: WILEY , 111 RIVER ST, HOBOKEN, USA, NJ, 07030-5774

ISSN / eISSN: 1445-937X / 2055-2335

Web of Science Core Collection: Emerging Sources Citation Index

Additional Web of Science Indexes: Biological Abstracts | BIOSIS Previews

[Share This Journal](#)

[View profile page](#)

\* Requires free login.

## JOURNAL OF RESEARCH IN PHARMACY

Publisher: MARMARA UNIV, FAC PHARMACY , Recep Tayyip Erdogan Campus, Basibuyuk 4/A, Maltepe, ISTANBUL, Turkiye, 34854

ISSN / eISSN: 2630-6344

Web of Science Core Collection: Emerging Sources Citation Index

[Share This Journal](#)

[View profile page](#)

\* Requires free login.

## JOURNAL OF RESEARCH IN PHARMACY PRACTICE

OPEN ACCESS

Publisher: WOLTERS KLUWER MEDKNOW PUBLICATIONS , Wolters Kluwer India Pvt Ltd (Medknow) Fourth Floor, East Wing, Marisoft III, Marisoft Premises, (Part of Software Technology Park), S. NO. 15, Vadgaon Sheri, Kalyani Nagar, Pune, India, Maharashtra, 411014

ISSN / eISSN: 2319-9644 / 2279-042X

Web of Science Core Collection: Emerging Sources Citation Index

[Share This Journal](#)

[View profile page](#)

\* Requires free login.

## PHARMACOGNOSY RESEARCH

Publisher: PHCOG NET , 17, 2ND FLR, BUDDHA VIHAR RD, NEAR SPORTS ZONE, COX TOWN, BENGALURU, KARNATAKA, INDIA, 560005

ISSN / eISSN: 0974-8490 / 0976-4836  
Web of Science Core Collection: Emerging Sources Citation Index

[Share This Journal](#)

[View profile page](#)

\* Requires free login.

## RESEARCH IN SOCIAL & ADMINISTRATIVE PHARMACY

Publisher: ELSEVIER SCIENCE INC , STE 800, 230 PARK AVE, NEW YORK, USA, NY, 10169

ISSN / eISSN: 1551-7411 / 1934-8150

Web of Science Core Collection: Social Sciences Citation Index

Additional Web of Science Indexes: Current Contents Social And Behavioral Sciences | Essential Science Indicators

[Share This Journal](#)

[View profile page](#)

\* Requires free login.

## JOURNAL OF PHARMACY AND BIOALLIED SCIENCES

OPEN ACCESS

Publisher: WOLTERS KLUWER MEDKNOW PUBLICATIONS , Wolters Kluwer India Pvt Ltd (Medknow) Fourth Floor, East Wing, Marisoft III, Marisoft Premises, (Part of Software Technology Park), S. NO. 15, Vadgaon Sheri, Kalyani Nagar, Pune, India, Maharashtra, 411014

ISSN / eISSN: 0976-4879 / 0975-7406

Web of Science Core Collection: Emerging Sources Citation Index

[Share This Journal](#)

[View profile page](#)

\* Requires free login.

Items per page: 10

1 – 10 of 22646

[|<](#) [<](#) [>](#) [>|](#)

**Editorial Disclaimer:** As an independent organization, Clarivate does not become involved in and is not responsible for the editorial management of any journal or the business practices of any publisher. Publishers are accountable for their journal performance and compliance with ethical publishing standards. The views and opinions expressed in any journal are those of the author(s) and do not necessarily reflect the views or opinions of Clarivate. Clarivate remains neutral in relation to territorial disputes, and allows journals, publishers, institutes and authors to specify their address and affiliation details including territory.

Criteria for selection of newly submitted titles and re-evaluation of existing titles in the Web of Science are determined by the Web of Science Editors in their sole discretion. If a publisher's editorial policy or business practices negatively impact the quality of a journal, or its role in the surrounding literature of the subject, the Web of Science Editors may decline to include the journal in any Clarivate product or service. The Web of Science Editors, in their sole discretion, may remove titles from coverage at any point if the titles fail to maintain our standard of quality, do not comply with ethical standards, or otherwise do not meet the criteria determined by the Web of Science Editors. If a journal is deselected or removed from coverage, the journal will cease to be indexed in the Web of Science from a date determined by the Web of Science Editors in their sole discretion – articles published after that date will not be indexed. The Web of Science Editors' decision on all matters relating to journal coverage will be final.

**[Clarivate.™ Accelerating innovation.](#)**



# Journal of Pharmacy & Pharmacognosy Research

## JPPRes

📞 0719-4250 (ONLINE)

Website

ISSN Portal

About Articles

### PUBLISHING WITH THIS JOURNAL

💰 The journal charges up to:

**600 USD**

as [publication fees](#) (article processing charges or APCs).

There is **no waiver policy** for these charges.

🔍 Look up the journal's:

- [Aims & scope](#)
- [Instructions for authors](#)
- [Editorial Board](#)
- [Peer review](#)

→ This journal checks for plagiarism

🕒 Expect on average **12 weeks** from submission to publication.

### BEST PRACTICE

📅 This journal began publishing in **open access in 2013**. [?](#)

This journal uses a **CC BY-NC-ND** license.



→ Look up their [license terms](#).

© The author **does not retain unrestricted** copyrights and publishing rights.

→ Learn more about their [copyright policy](#).

📁 Deposit policy with:

- [Open Policy Finder](#)

### JOURNAL METADATA

📍 Publisher  
[GarVal Editorial Ltda.](#), Chile

Manuscripts accepted in English, Spanish

📁 LCC subjects [?](#)  
[Medicine: Therapeutics.](#)  
[Pharmacology.](#)  
[Medicine: Pharmacy and materia medica](#)

Keywords  
pharmacy    pharmacognosy  
  
phytomedicine  
  
phytotherapy  
  
pharmacology  
  
complementary medicine



SEARCH

Journals

Articles

DOCUMENTATION

API

OAI-PMH

Widgets

Public data dump

OpenURL

XML

Metadata help

Preservation

ABOUT

About DOAJ

DOAJ at 20

DOAJ team

Ambassadors

Foundation and Advisory Boards

Editorial Policy Advisory Group

Volunteers

News

SUPPORT

Institutions and libraries

Publishers

Institutional and library supporters

Funders

APPLY

Application form

Guide to applying

Transparency & best practice

Publisher information

Licensing & copyright

STAY UP TO DATE

Twitter

Facebook

Github

Linkedin

WeChat

Atom feed



## Journal of Pharmacy &amp; Pharmacognosy Research



English title: Journal of Pharmacy &amp; Pharmacognosy Research

ISSN: 0719-4250 (online)

DOI: *n/d*Website: <http://jppres.com/jppres> (<http://jppres.com/jppres>)

Publisher: JPPRes, Journal of Pharmacy &amp; Pharmacognosy Research

Country: CL

Language of publication: ES

Deposited publications: 191 &gt; Full text: 97% | Abstract: 100% | Keywords: 96% | References: 0%

[Issues and contents](#)[Journal description \(\)](#)[Details \(\)](#)[Scientific profile \(\)](#)[Editorial office \(\)](#)

## Publisher ()

The Journal of Pharmacy & Pharmacognosy Research (JPPRes) is an international, specialized and peer-reviewed open access journal, which publishes studies in the pharmaceutical and herbal fields concerned with the physical, botanical, chemical, biological, toxicological properties and clinical applications of molecular entities, active pharmaceutical ingredients, devices and delivery systems for drugs, vaccines and biologicals, including their design, manufacture, evaluation and marketing. This journal publishes research papers, reviews, commentaries and letters to the editor as well as special issues and review of pre-and post-graduate thesis from pharmacists or professionals involved in Pharmaceutical Sciences or Pharmacognosy. JPPRes has an acceptance rate of 40.5%. The average time between submission and final decision is 70 days and the average time between acceptance and final publication is 15 days. JPPRes accepts, in English or Spanish, review articles, articles for educational forum, original research articles (full length and short communications), letter to editor and case reports. Articles concerning all aspects of Pharmacy and Pharmacognosy will be considered. Articles of general interest (e.g. methods, therapeutics, medical education, interesting websites, new drug information and commentary on a recent topic) are also welcome. Manuscripts submitted to JPPRes are only accepted on the understanding that they are subject to editorial review and that they have not been, and will not be, published in whole or in part in any other journal. JPPRes considers only original contributions submitted exclusively to the journal. Prior and duplicate publications are not allowed. Publication of abstract under conference proceedings will not be considered as prior publication. It is the duty of the authors to inform the JPPRes about all submissions and previous reports that might be regarded as prior or duplicate publication.

Non-indexed in the ICI Journals Master List 2024

Not reported for evaluation

[Archival ratings >](#)

MSHE points:

20 pkt

[Find similar](#)[Main page \(http://jml.indexcopernicus.com\)](http://jml.indexcopernicus.com)[Rules](#)

20 pkt - pharmacology and pharmacy, biotechnology, medical biology, veterinary science, horticulture

I N T E R N A T I O N A L

[http://indexcopernicus.com/images/PDF/Regulamin\\_serwisu\\_internetowego.pdf](http://indexcopernicus.com/images/PDF/Regulamin_serwisu_internetowego.pdf) (<http://indexcopernicus.com>)

(http://indexcopernicus.com)

European Union  
European Regional  
Development Fund[Privacy policy](#)

As part of our website we use cookies to provide you with services at the highest level, including in a manner tailored to individual needs. Using the site without changing the settings for cookies results in saving them in your device. You can change cookies' settings any time you want in your web browser. More details in our

[Cookies Policy](#)[Return policy](#)

Get it!





Journal of Pharmacy  
& Pharmacognosy  
Research

CELEBRATING  
**10** YEARS  
2013-2023

## Editorial Board

Journal of Pharmacy  
& Pharmacognosy  
Research

### Marisela Valdés González

Executive Editor

[ORCID](#)

GarVal Editorial Ltda.

[Email](#)

### Gabino Garrido

Editor-in-Chief

[Scholar Google](#)[Scopus](#)[ResearchGate](#)[ORCHID](#)

GarVal Editorial Ltda.

[Email](#)

### Xavier Garrido

Editorial and Design Manager

[LinkedIn](#)[Behance](#)[Web](#)

AVAGAX Studio

Antofagasta, Chile

[Email](#)

## Editorial Board Members



### Antonio Vassallo

Dipartimento di Scienze.  
Università degli Studi della  
Basilicata, Potenza, Italia.



### Bárbara B. Garrido Suárez

Laboratorio de Farmacología  
y Toxicología, Centro de  
Investigación y Desarrollo de



### Carla Delporte

Facultad de Ciencias  
Químicas y Farmacéuticas,



### Damaris Silveira

Faculdade de Ciências da  
Saúde, Universidade de  
Brasília, Brazil

[Scopus](#)
[ORCID](#)
[ORCID](#)
[ORCID](#)


**Douglas S. de Almeida Chaves**

Dep. de Ciências Farmacêuticas (DCFAR), Instituto de Ciências Biológicas e da Saúde, Universidade Federal Rural do Rio de Janeiro, Rodovia, RJ. Brazil

[ResearchGate](#)
[ORCID](#)
[Lattes](#)


**Edgar Pastene**

Universidad de Concepción, Concepción, Chile

[ResearchGate](#)
[ORCID](#)


**Etile Spegazzini**

Universidad de Belgrano, Buenos Aires, Argentina

[ResearchGate](#)


**Farid Chemat**

Université Avignon et des Pays de Vaucluse, Avignon, France

[ResearchGate](#)


**Fidel O. Castro**

Departamento de Ciencias Pecuarias, Universidad de Concepción, Chillán, Chile

[ResearchGate](#)
[ORCID](#)


**Guilherme N. L. do Nascimento**

Universidade Federal de Tocantins. Brazil

[ORCID](#)


**Jacqueline Sepúlveda**

Universidad de Concepción, Concepción, Chile

[ResearchGate](#)
[ORCID](#)


**Jelena Nadinic**

Universidad de Buenos Aires, Argentina.

[ResearchGate](#)
[ORCID](#)


**José H. Isaza-Martínez**

Universidad del Valle, Cali, Colombia



**Juan C. Sepúlveda-Arias**

Universidad Tecnológica de Pereira, Pereira, Colombia



**Madan Mohan Gupta**

School of Pharmacy, Faculty of Medical Sciences. The



**Mahomoodally M. Fawzi**

Department of Health Sciences, Faculty of Science,

ORCID

ORCID

ORCID

ResearchGate



### María Inés Isla

Facultad de Ciencias Naturales e Instituto Miguel Lillo. Universidad Nacional de Tucumán, Tucumán, Argentina.

ResearchGate

ORCID



### Marisol Fernández Alfonso

Facultad de Farmacia, Universidad Complutense de Madrid, España

ResearchGate

ORCID



### Mayank Gangwar

Department of Pharmacology, Institute of Medical Sciences, Banaras Hindu University, Varanasi (UP) India

Scholar Google

ORCID



### Silvia Debenedetti

Pharmacy Career. Universidad de Belgrano, Buenos Aires, Argentina

ORCID

ResearchGate



### Vikash Kumar Ruhil

PDM College of Pharmacy, Bahadurgarh, Haryana, India

Google Scholar



### Yasser Shahzad

Department of Pharmacy. COMSATS University Islamabad, Pakistan

Scopus

ORCID

Google Scholar

## Reviewers

The reviewers will be recruited among researchers and clinicians with high international reputation in Pharmacy and Pharmacognosy.

*Last Update: August 20th, 2023*



# JPPRes

Journal of Pharmacy  
& Pharmacognosy  
Research



[Submit Article](#)

---

© 2013-2020 by the authors; licensee JPPRes, Antofagasta, Chile. This journal is an open-access journal distributed under the terms and conditions of the Creative Commons Attribution license-Non Commercial 4.0 international. The content on this site is intended for health professionals. If you are not a health professional, please talk to your doctor about any doubts or concerns regarding your health

Made with ♥ by **AVAGAX Studio**

## Volume 11, Issue 2

J Pharm Pharmacogn Res 11(2), (Mar–Apr) 2023



IFC (Journal of Pharmacy & Pharmacognosy Research).

### 1.- Original Article

Dini Kesuma, Aguslina Kirtishanti, Citra H.A. Makayasa, I Gede A. Sumartha (2023) **Anticancer activity of N-(4-t-butylbenzoyl)-N'-phenylthiourea: Molecular docking, synthesis, and cytotoxic activity in breast and cervical cancer cells.** | [Actividad anticancerígena de la N-(4-t-butylbenzoyl)-N'-feniltiourea: acoplamiento molecular, síntesis y actividad citotóxica en células de cáncer de mama y de cuello uterino]. J Pharm Pharmacogn Res 11(2): 208–215. [https://doi.org/10.56499/jppres22.1508\\_11.2.208](https://doi.org/10.56499/jppres22.1508_11.2.208)  jppres\_pdf\_free[640 Kb]

### 2.- Original Article

Maria R. Ramirez, Ignacio Rintoul, Manuel Leiva, José S. Molli, Juan C. Yori (2023) **Oral supplementation of *Ilex paraguariensis* extract and eggshell membrane exhibit beneficial effects on the skin of mature male rats.** | [La suplementación oral de extracto de *Ilex paraguariensis* y membrana de cáscara de huevo muestran efectos beneficiosos sobre la piel de ratas macho maduras]. J Pharm Pharmacogn Res 11(2): 216–228. [https://doi.org/10.56499/jppres22.1509\\_11.2.216](https://doi.org/10.56499/jppres22.1509_11.2.216)  jppres\_pdf\_free[955 Kb]

### 3.- Original Article

Hassan Sohrabian Kafraj, Maryam Alipour, Abdolhosein Shiravi, Vida Hojati, Mojtaba Khaksarian (2023) **Chitosan-alginate porous scaffold incorporated with hydroalcoholic *Zingiber officinale* Roscoe extract for neural tissue engineering.** | [Estructura porosa de quitosano-alginato incorporada con extracto hidroalcohólico de *Zingiber officinale* Roscoe para la ingeniería del tejido neural]. J Pharm Pharmacogn Res 11(2): 229–242. [https://doi.org/10.56499/jppres22.1505\\_11.2.229](https://doi.org/10.56499/jppres22.1505_11.2.229)  jppres\_pdf\_free[1.26 Mb]

### 4.- Original Article

Bhujangga Agung Ayu Sri Kartika Dewi, Kartini Kartini (2023) **System optimization and validation to improve thin-layer chromatography of roselle calyces (*Hibiscus sabdariffa* L.) required by the Indonesian Herbal Pharmacopoeia Edition II.** | [Optimización y validación del sistema para mejorar la cromatografía en capa fina de cálices de rosa mosqueta (*Hibiscus sabdariffa* L.) requerida por la Farmacopea Herbal Indonesia Edición II]. J Pharm Pharmacogn Res 11(2): 243–254. [https://doi.org/10.56499/jppres22.1566\\_11.2.243](https://doi.org/10.56499/jppres22.1566_11.2.243)  jppres\_pdf\_free[699 Kb]

### 5.- Original Article

Dita Maria Virginia, Christine Patramurti, Phebe Hendra, Paulina Nadya Feranti Pebby Lorenza, Faustina Evania Ngai, Novita Anastasia, Matea Nirmala Defi, Mae Sri Hartati Wahyuningsih, Dwi Aris Agung Nugrahaningsih (2023) **The mutant of rs2075604 in *STK11* improves HDL-c levels among newly diagnosed type 2 diabetes mellitus patients.** | [El mutante de rs2075604 en *STK11* mejora los niveles de HDL-c entre los pacientes con diabetes mellitus tipo 2 recién diagnosticada]. J Pharm Pharmacogn Res 11(2): 255–262. [https://doi.org/10.56499/jppres22.1541\\_11.2.255](https://doi.org/10.56499/jppres22.1541_11.2.255)  jppres\_pdf\_free[463 Kb]

---

**7.- Original Article**

Felipe Surco-Laos, Jorge A. Garcia, María R. BendeZú, Angel T. Alvarado, Doris Laos-Anchante, Manuel Valle-Campos, Juan F. Panay-Centeno, Juan J. Palomino-Jhong, Paulina Eliades Yarasca-Carlos, Ana María Muñoz, Mario Bolarte-Arteaga, Mario Pineda, Berta Loja (2023) **Characterization of polyunsaturated fatty acids and antioxidant activity of *Vitis vinifera* L. (grape) seeds from the Ica Valle Peru.** | [Caracterización de ácidos grasos poliinsaturados y actividad antioxidante de las semillas de *Vitis vinifera* L. (uva) del valle de Ica, Perú]. J Pharm Pharmacogn Res 11(2): 270-280. [https://doi.org/10.56499/jppres23.1575\\_11.2.270](https://doi.org/10.56499/jppres23.1575_11.2.270)  jppres\_pdf\_free [910 Kb]

---

**8.- Original Article**

Hala F. Kasim (2023) **Prevalence of potential drug interactions among outpatients' prescriptions of community pharmacies in Nineveh Governorate, Iraq.** | [Prevalencia de posibles interacciones farmacológicas entre las recetas de los pacientes ambulatorios de las farmacias comunitarias de la gobernación de Nínive, Iraq]. J Pharm Pharmacogn Res 11(2): 281-290. [https://doi.org/10.56499/jppres23.1577\\_11.2.281](https://doi.org/10.56499/jppres23.1577_11.2.281)  jppres\_pdf\_free [344 Kb]

---

**9.- Original Article**

Monika Kerry Army, Rohimatul Khodijah, Yuli Haryani, Hilwan Yuda Teruna, Rudi Hendra (2023) **Antibacterial *in vitro* screening of *Helminthostachys zeylanica* (L.) Hook. root extracts.** | [Cribado antibacteriano *in vitro* de extractos de raíz de *Helminthostachys zeylanica* (L.) Hook.]. J Pharm Pharmacogn Res 11(2): 291-296. [https://doi.org/10.56499/jppres22.1540\\_11.2.291](https://doi.org/10.56499/jppres22.1540_11.2.291)  jppres\_pdf\_free [349 Kb]

---

**10.- Original Article**

Yurnadi Hanafi Midoen, Syafruddin Ilyas, Putra Santoso, Putri Cahaya Situmorang (2023) **Effect of maximal physical exercise on apoptosis via cytochrome c in hippocampus cells after administration of *Vitis gracilis* Wall.** | [Efecto del ejercicio físico máximo sobre la apoptosis vía citocromo c en células del hipocampo tras la administración de *Vitis gracilis* Wall.]. J Pharm Pharmacogn Res 11(2): 297-307. [https://doi.org/10.56499/jppres22.1563\\_11.2.297](https://doi.org/10.56499/jppres22.1563_11.2.297)  jppres\_pdf\_free [1.02 Mb]

---

**11.- Original Article**

Quranayati Quranayati, Nurdin Saidi, Nurliana Nurliana, Rinaldi Idroes, Naufal Gusti, Rosnani Nasution (2023) **Effect of *Phyllanthus emblica* L. stem bark extract on diabetic nephropathy and hyperlipidemia in rats.** | [Efecto del extracto de corteza de tallo de *Phyllanthus emblica* L. sobre la nefropatía diabética y la hiperlipidemia en ratas]. J Pharm Pharmacogn Res 11(2): 308-314. [https://doi.org/10.56499/jppres23.1595\\_11.2.308](https://doi.org/10.56499/jppres23.1595_11.2.308)  jppres\_pdf\_free [434 Kb]

---

**12.- Original Article**

Fatchiyah Fatchiyah, Dewi Ratih Tirta Sari, Hazna Noor Meidinna, Nia Kurnianingsih, Ema Pristi Yunita, Sinta Murlistyarini (2023) **Stability evaluation and heavy metal quantification of lotions from caprine milk, yogurt, and kefir.** | [Evaluación de la estabilidad y cuantificación de metales pesados en lociones de leche caprina, yogur y kéfir]. J Pharm Pharmacogn Res 11(2): 315-324. [https://doi.org/10.56499/jppres22.1514\\_11.2.315](https://doi.org/10.56499/jppres22.1514_11.2.315)  jppres\_pdf\_free [1.25 Mb]

---

**13.- Original Article**

Syamsu Nur, Muhammad Hanafi, Heri Setiawan, Nursamsiar, Berna Elya (2023) ***In silico* evaluation of the dermal antiaging activity of *Molineria latifolia* (Dryand. ex W.T. Aiton) Herb. Ex Kurz compounds.** | [Evaluación *in silico* de la actividad antienvjecimiento dérmic de compuestos de *Molineria latifolia* (Dryand. ex W.T. Aiton) Herb. ex Kurz]. J Pharm Pharmacogn Res 11(2): 325-345. [https://doi.org/10.56499/jppres23.1606\\_11.2.325](https://doi.org/10.56499/jppres23.1606_11.2.325)  jppres\_pdf\_free [2.69 Mb]

---

**14.- Original Article**

Cristian Valiente, Silvana Alvariza, Diego M. Robaina, Gonzalo Suárez (2023) **Development and validation of UHPLC method for the determination of fluazuron in bovine tissues.** | [Desarrollo y validación de método UHPLC para la determinación de fluazuron en tejidos bovinos]. J Pharm Pharmacogn Res 11(2): 346-353. [https://doi.org/10.56499/jppres22.1548\\_11.2.346](https://doi.org/10.56499/jppres22.1548_11.2.346)  jppres\_pdf\_free [559 Kb]

---





# The mutant of rs2075604 in *STK11* improves HDL-c levels among newly diagnosed type 2 diabetes mellitus patients

[El mutante de rs2075604 en *STK11* mejora los niveles de HDL-c entre los pacientes con diabetes mellitus tipo 2 recién diagnosticada]

Dita Maria Virginia<sup>1\*</sup>, Christine Patramurti<sup>1</sup>, Phebe Hendra<sup>1</sup>, Paulina Nadya Feranti Pebby Lorenza<sup>1</sup>, Faustina Evania Ngai<sup>1</sup>, Novita Anastasia<sup>1</sup>, Matea Nirmala Defi<sup>1</sup>, Mae Sri Hartati Wahyuningsih<sup>2</sup>, Dwi Aris Agung Nugrahaningsih<sup>2,3</sup>

<sup>1</sup>Faculty of Pharmacy, Sanata Dharma University, DI Yogyakarta, Indonesia.

<sup>2</sup>Department of Pharmacology and Therapy, Faculty of Medicine, Public Health, and Nursing, Universitas Gadjah Mada, DI Yogyakarta, Indonesia.

<sup>3</sup>Center of Genetic Study, Faculty of Medicine, Public Health, and Nursing, Universitas Gadjah Mada, DI Yogyakarta, Indonesia.

\*E-mail: [virginia@usd.ac.id](mailto:virginia@usd.ac.id)

## Abstract

**Context:** Type 2 diabetes mellitus (T2DM) patients tend to have lipid abnormalities, thus elevating the risk of complications and mortality. Early detection using a genomic approach could help identify the abnormality of lipid profiles so that it could reduce those burdens. A previous study found a high frequency of mutants in the rs2075604 as the intron area in the *STK11* gene.

**Aims:** To analyze the effect of rs2075604 related to lipid abnormalities in newly diagnosed T2DM patients.

**Methods:** This present study conducted a cross-sectional study in the ten public healthcare facilities in Sleman, Yogyakarta. The genetic variants were detected using PCR-RFLP methods. A total of 130 patients who had to consume antidiabetic oral for three months participated in this study.

**Results:** This study revealed that the mutant variant dominated in this population at 61.5%. Mutant genotype, mutant allele, and dominant model reduce the risk of low HDL (OR = 0.33, 95% CI = 0.11-0.99; OR = 0.46, 95% CI = 0.24-0.90; OR = 0.33, 95% CI = 0.12-0.96; respectively). The improvement of low HDL risk by the mutant allele was confirmed through an adjusted model (OR = 0.47, 95% CI = 0.23-0.98). The mutant allele only influenced high LDL risk in the non-adjusted model (OR = 2.22, 95% CI = 1.02-4.82), but it did not found in other models.

**Conclusions:** The mutant of rs2075604 has a protective role in low HDL-c risk in Indonesia. However, further study is required to observe the effect on LDL-c.

**Keywords:** rs2075604; *STK11*; lipid profiles; type 2 diabetes mellitus.

## Resumen

**Contexto:** Los pacientes con diabetes mellitus tipo 2 (DMT2) tienden a presentar anomalías lipídicas, lo que eleva el riesgo de complicaciones y mortalidad. La detección precoz mediante un enfoque genómico podría ayudar a identificar la anomalía de los perfiles lipídicos, de modo que podría reducir esas cargas. Un estudio anterior halló una alta frecuencia de mutantes en el rs2075604 como zona del intrón en el gen *STK11*.

**Objetivos:** Analizar el efecto del rs2075604 relacionado con las anomalías lipídicas en pacientes con DMT2 recién diagnosticados.

**Métodos:** El presente estudio llevó a cabo un estudio transversal en los diez centros sanitarios públicos de Sleman, Yogyakarta. Las variantes genéticas se detectaron mediante métodos PCR-RFLP. Participaron en este estudio 130 pacientes que debían consumir antidiabéticos orales durante tres meses.

**Resultados:** Este estudio reveló que la variante mutante dominaba en esta población con un 61,5%. El genotipo mutante, el alelo mutante y el modelo dominante reducen el riesgo de HDL bajo (OR = 0,33, IC 95% = 0,11-0,99; OR = 0,46, IC 95% = 0,24-0,90; OR = 0,33, IC 95% = 0,12-0,96; respectivamente). La mejora del riesgo de HDL bajo por el alelo mutante se confirmó mediante un modelo ajustado (OR = 0,47; IC 95% = 0,23-0,98). El alelo mutante sólo influyó en el riesgo de LDL alto en el modelo no ajustado (OR = 2,22; IC 95% = 1,02-4,82), pero no se encontró en otros modelos.

**Conclusiones:** El mutante del rs2075604 tiene un papel protector en el riesgo de HDL-c bajo en Indonesia. Sin embargo, se requieren más estudios para observar el efecto sobre LDL-c.

**Palabras Clave:** rs2075604; *STK11*; perfiles lipídicos; diabetes mellitus tipo 2.

## ARTICLE INFO

Received: November 22, 2022.

Accepted: February 26, 2022.

Available Online: March 26, 2023.

## AUTHOR INFO

ORCID:

[0000-0003-0469-1913](https://orcid.org/0000-0003-0469-1913) (DMV)

[0000-0002-2423-9695](https://orcid.org/0000-0002-2423-9695) (CP)

[0000-0002-1077-7847](https://orcid.org/0000-0002-1077-7847) (PH)

[0000-0002-9274-5573](https://orcid.org/0000-0002-9274-5573) (MSHW)

[0000-0002-1616-3053](https://orcid.org/0000-0002-1616-3053) (DAAN)

## INTRODUCTION

Indonesia is ranked 5<sup>th</sup> out of 10 countries with the most diabetic patients (Sun et al., 2022). Diabetes mellitus is the highest cause of death, and the prevalence of DM has increased by 1.6% in Indonesia (Kementerian Kesehatan, 2020). Type 2 diabetes mellitus (T2DM) is the major type of diabetes found in Indonesia, and the Sleman District had the highest number of T2DM in the Province of DI Yogyakarta. Therefore, this present study conducted a study in public health care in the Sleman District (Dinas, 2020).

On the other hand, several studies revealed that type 2 diabetes mellitus (T2DM) patients tend to have an abnormality of lipid profiles, significantly enhanced triglycerides serum, and reduced HDL-c (Hussain et al., 2017; Rusdiana et al., 2020). Lipid profile abnormalities are the major risk factors to increase complications and mortality due to cardiovascular disease (CVD) among T2DM patients (Ikhsan et al., 2022; Jayakumari et al., 2020; Suhadi et al., 2017). Furthermore, CVD accompanied by T2DM increases mortality risk, and the evidence was reported higher in South East Asia (Ma et al., 2022). Therefore, prevention detection and strategies are required to reduce lipid abnormalities and minimize CVD risk.

Genetic factors have been confirmed involving the susceptibility of T2DM and its complications. The combined analysis of genetic and environmental factors could predict the risk of lipid abnormalities in T2DM patients (Dietrich et al., 2019; Li et al., 2020). Over the past three decades, most studies in pharmacogenomics have increased surprisingly. Genome-wide association study (GWAS) assured that genetic variation in several genes induces lipid abnormalities in T2DM patients, including *APOB*, *HNF4*, *LPL*, *ABCA1*, *ABCC8*, *PRKAA2*, *SCARB1*, and *ADIPOQ* (Cai et al., 2017; Nicchio et al., 2021; Vardarli et al., 2017). In addition, several studies have performed to detect any association between genetic and CVD risk (Virginia et al., 2021; 2022). Eventually, the non-coding region of single nucleotide polymorphism (SNP) could be a predictor (Witka et al., 2019). Accordingly, the pharmacogenomic approach should be considered a tool for early detection.

One gene which has yet to be explored is *STK11*. *STK11* gene, encoding liver kinase B1 (LKB1), is located on chromosome 19:1218524 (GRCh38). The selection of SNP rs2075604 was due to the high mutant of 46.6% in Vietnamese, a region of South East Asia. However, there has been no publication regarding the frequency of *STK11* rs2075604 mutations in Indonesia. SNP rs2075604 is the intron part of *STK11*. The results of research conducted by Kumari et al. (2022) and

Rose (2018) stated that genetic variations in introns could regulate gene expression and affect splicing so that it has a probability of disrupting protein expression. The existence of this SNP can have the potential affected to LKB1 activity. Thus it will also affect abnormality lipid profiles.

Previous studies have confirmed several SNP contributing to enhancing lipid abnormality in T2DM. However, *STK11* rs2075604 has only been observed in the Chinese population related to metformin efficacy (Li et al., 2017). This was the first study reporting the influence of rs2075604 on lipid profile abnormality, especially in Indonesia. Detection of *STK11* rs2075604 mutations could be a part of preventing action for improving ASCVD risk since this recent study was observing newly diagnosed T2DM patients. Therefore, the present study aimed to explore the effect of variant rs2075604 in *STK11* with an abnormality of lipid profiles in T2DM patients.

## MATERIAL AND METHODS

The study conducted a cross-sectional study design. The protocol for genetic variant identification has been reviewed and approved by the Ethics Committee of Universitas Respati Yogyakarta (protocol number: 115.3/FIKES/PL/VII/2022). All participants have signed informed consent in the previous study and approved by the Medical and Health Research Ethics Committee (MHREC) Faculty of Medicine, Public Health, and Nursing Universitas Gadjah Mada - Dr. Sardjito General Hospital, Indonesia. The research conducted in ten primary health care in Yogyakarta, Indonesia. This study used a convenience sample of 130 participants based on inclusion and exclusion criteria. The inclusion criteria were newly diagnosed T2DM patients (according to American Diabetes Association (ADA) criteria (American Diabetes Association, 2020), who consumed metformin, sulfonylurea, and/or acarbose at least three months, were 18-70 years old, and had national health insurance. Participants who were prescribed insulin, DPP-IV inhibitor, SGLT-2 inhibitor, and/or GLP-1 receptor agonist were excluded. Patients diagnosed cardiovascular diseases and cancer also excluded.


### Clinical parameters measurement

The nutritionist measured body weight, height, and waist circumference. A nurse measured blood pressure. Fasting blood glucose (FBG), HbA1c, total cholesterol, HDL-c, LDL-c, and triglycerides were examined after participants fasted during 8-10 hours. FBG was measured using the hexokinase method (Freeman, 2014). HbA1c and lipid profiles (total cho-

lesterol, HDL-c, and triglycerides) were assayed using high-performance liquid chromatography (Cobas D-10 and Cobas C311, respectively) (Kahena et al., 2013; Moustapha et al., 2020). The present study applied Friedewald formulation to calculate the LDL-c level (Friedewald et al., 1972). Data of family history of T2DM and smoking status were collected from the questionnaire.

### Isolation of DNA and SNP rs2075604 detection

Peripheral blood samples were collected from participants in an EDTA tube. DNA was isolated according to the kit protocol (Geneaid® Blood DNA Mini K) and stored at -70°C until the genotyping procedure was done (Yamagata et al., 2021). The SNP rs2075604 was identified using the dbSNP database as the National Centre of Biotechnology Information (NCBI, 2022). The primer pair of rs2075604, which was designed for this study, was: forward (5'-GTACGCCACTTCCACAGG-3') and reverse (5'-AAAGGGACTTGACACCCAC-3') from MacroGen®. The PCR and restriction fragment length polymorphism (RFLP) was done to detect *STK11* rs2075604. The final volume for the PCR reaction is 25 µL. The thermal cycler for a PCR was as follows: denaturation at 95°C, annealing at 57.5°C, and extension at 72°C. BstUI as a restriction enzyme (Thermoscientific®) at CG/CG was used to detect the rs2075604. The results of SNP 2075604 are presented in Fig. 1.



**Figure 1.** The results of electrophoresis related to SNP 2075604 detection through PCR-RFLP method.

W: wildtype homozygote (GG); M: mutant homozygote (TT); H: heterozygote (GT); L: ladder 100 bp.

### Statistical analysis

The profiles of participants' characteristics are presented as n (percentage) for categorical data and mean  $\pm$  SD for numerical data. The correlation of glycemia indicator and lipid profiles was analyzed using Pearson. Chi-square tests were performed to calculate Odd Ratio (OR) and 95% CI (confidence interval)

describing the association between rs2075604 and lipid profile abnormality. For the association analysis, HDL-c below 40 mg/dL, LDL-c over 130 mg/dL, triglycerides below 150 mg/dL, and/or total cholesterol over 200 mg/dL were considered as a high-risk group. An adjustment for those factors was analyzed using logistic regression to reduce confounding factors, including age, gender, BMI, waist circumstances, blood pressure, HbA1c level, fasting plasma glucose level, and smoking status. Significant statistically were defined through  $p < 0.05$ . All statistical analysis using SPSS.

## RESULTS

Characteristics of 130 newly diagnosed T2DM patients with regard to all demographic and clinical measurements are shown in Table 1. All participants received diabetes therapy for three months after being diagnosed. Since only newly diagnosed patients were recruited in this study and related to exclusion criteria, there were no patients diagnosed with cardiovascular diseases and cancer. Females, with no family history of T2DM, and passive smokers are dominant among participants. The majority patients tend to be obese according to BMI classification in the Asian population. As descriptive analysis results, the mean of blood pressure, total cholesterol, HDL-c, LDL-c, and triglyceride levels were in the standard criteria, relatively.

A total of mutant genotypes among participants reached 61.9%. In detail, TT = 61.6%, GT = 19.2%, and GG = 19.1%. Fig. 2 summarizes the distribution of high-risk vs. normal lipid profiles in the genotype of rs2075604. All lipid profiles have found a higher percentage as normal criteria in each rs2075604 genotype. Table 2 presents a correlation analysis of clinical data between the hyperglycemia indicator and lipid profile level. The most interesting finding in Table 2 is that increasing the HbA1c level could reduce LDL-c significantly statistically ( $r = -0.20$ ,  $p = 0.02$ ). All lipid profiles appeared to be unaffected by FBG.

The association of rs2075604 and lipid profile abnormalities is presented in Table 3, either in crude/non-adjusted odds ratio or adjusted odds ratio. TT as mutant homozygote genotype, T allele as mutant allele, and dominant model had significant association statistically with low HDL-c level (OR = 0.33, 95% CI = 0.11-0.99,  $p = 0.049$ ; OR = 0.46, 95% CI = 0.24-0.90,  $p = 0.02$ , respectively). Interestingly, after adjusting by confounding factors, only the T allele was associated with low HDL-c (AOR = 0.47, 95% CI = 0.23-0.98,  $p = 0.04$ ). Furthermore, there was a statistically significant association of rs2075604 with a low-HDLc level in the dominant model without adjust-

ment by confounder. The presence of the TT + GT genotype demonstrated a lower risk of low HDL-c (TT + GT *vs.* GG: OR = 0.33, 95%CI = 0.12-0.96, *p* = 0.04).

In model 1, this study found that the T allele significantly increased high LDL-c risk statistics (OR = 2.22, 95% CI = 1.02-4.82, *p* = 0.04). However, after adjusting for the confounder, there was no significant association between rs2075604 and high LDL-c (*p*>0.05). This research could not find any significant association between rs2075604 and high total cholesterol and triglyceride levels (*p*>0.05).

## DISCUSSION

*STK11* is a gene encoding LKB1 that plays a vital role in gluconeogenesis in the liver. LKB1 induces AMPK activation and thus mediates glucose homeostasis in the part of gluconeogenesis processed (Jeon, 2016). LKB1 could suppress amino-acid-driven gluconeogenesis (Just et al., 2020) and affect glucose levels and lipid profiles accordingly. The conformational changes of LKB1 caused by mutation might direct increase blood glucose levels and lipid profiles (Sokolova et al., 2019; Zhang et al., 2019). Recently, several polymorphisms of *STK11* has detected, including rs2075604, rs9282860, and rs8111699. *STK11* genetic variants are related to T2DM risk, metformin effectivity, and cancer (Dawed et al., 2016; Keshavarz et al., 2008; Li et al., 2017).

The previous study on Spanish girls with hyperinsulinemia revealed that *STK11* rs8111899 influences insulin sensitivity and metformin efficacy (López-Bermejo et al., 2010). *STK11* rs2075604 has previously studied metformin efficacy, and it was declared that rs2075604 had a significant association with metformin efficacy. GT carriers could achieve better efficacy compared to wildtype (Li et al., 2017). Thus, the present research investigate the effect of genetic variants in the rs2075604 and lipid profiles. From the literature study discovering, this is the first study that investigated the effect of *STK11* rs2075604 genetic variants and lipid profile abnormalities in Indonesia T2DM patients. In addition, this recent study restricts any confounding factors, especially T2DM duration and therapeutic, because this study only recruited newly diagnosed T2DM in three months.

The participants tend to have normal lipid profiles, which might be backgrounded from new T2DM patients. However, in each genotype, more than 10% of patients had abnormal lipid profiles. Awareness of this condition should be increased because abnormality of lipid profiles tends to be found in T2DM patients. Thus, these lipid abnormalities increase ASCVD risk and mortality (Rusdiana et al., 2020; Suhadi et al., 2017). The pharmacogenetic approach could help to predict the risk of lipid abnormalities among T2DM patients; accordingly, healthcare professionals could give appropriate and personalized therapy.

**Table 1.** The profiles of participant's characteristics.


| Characteristics                            | n (%) / mean ± SD             |
|--------------------------------------------|-------------------------------|
| Gender (male)                              | 36 (27.7)                     |
| Age (years old)                            | 56.31 ± 44.68                 |
| BMI (kg/m <sup>2</sup> )                   | 25.22 ± 3.82                  |
| Waist circumstanes (cm)                    | 88.05 ± 9.44                  |
| Blood pressure (mmHg) (systolic/diastolic) | 125.52 ± 11.57 / 79.65 ± 6.47 |
| Total cholesterol (mg/dL)                  | 185.90 ± 33.93                |
| HDL-c (mg/dL)                              | 47.35 ± 8.48                  |
| LDL-c (mg/dL)                              | 110.65 ± 31.58                |
| Triglycerides (mg/dL)                      | 139.28 ± 83.58                |
| HbA1c (%)                                  | 8.12 ± 1.31                   |
| FBG (mg/dL)                                | 143.98 ± 39.05                |
| Family history (yes)                       | 16 (12.3)                     |
| Smoking status (active smoker)             | 20 (15.4)                     |
| <b>Antidiabetic treatment</b>              |                               |
| Monotherapy metformin                      | 94 (72.3)                     |
| Metformin+glimepiride                      | 36 (27.7)                     |

BMI: body mass index, HDL-c: high density lipoprotein cholesterol, LDL-c: low density lipoprotein cholesterol; FBG: fasting blood glucose.

**Table 2.** The correlation of glycemia indicators (HbA1c and fasting blood glucose) and lipid profiles.

| Glycemia indicators | Total cholesterol |      | HDL-c |      | LDL-c |       | Triglycerides |      |
|---------------------|-------------------|------|-------|------|-------|-------|---------------|------|
|                     | r                 | p    | r     | p    | r     | p     | r             | p    |
| HbA1c               | -0.15             | 0.09 | -0.03 | 0.75 | -0.20 | 0.02* | 0.08          | 0.35 |
| FBG                 | -0.04             | 0.66 | -0.11 | 0.21 | -0.10 | 0.24  | 0.17          | 0.05 |

FBG: fasting blood glucose. \*p&lt;0.05

**Figure 2.** The distribution of lipid profiles according to *STK11* rs2075604 genotype.Distribution of *STK11* rs2075604 related to normal vs. high risk of (A) Total cholesterol; (B) HDL-c; (C) LDL-c; and (D) Triglycerides. GG: wildtype homozygote; GT: heterozygote; TT: mutant homozygote.**Table 3.** The association between rs2075604 with the abnormality of lipid profiles.

| Groups          | High total cholesterol level |         | Low HDL-c level  |         | High LDL-c level  |         | High triglycerides level |         |
|-----------------|------------------------------|---------|------------------|---------|-------------------|---------|--------------------------|---------|
|                 | OR (95%CI)                   | p-value | OR (95%CI)       | p-value | OR (95%CI)        | p-value | OR (95%CI)               | p-value |
| <b>Model 1</b>  |                              |         |                  |         |                   |         |                          |         |
| TT              | 1.61 (0.54-4.82)             | 0.39    | 0.33 (0.11-0.99) | 0.049*  | 2.61 (0.71-9.63)  | 0.15    | 0.91 (0.35-2.32)         | 0.84    |
| GT              | 1.56 (0.42-5.78)             | 0.51    | 0.35 (0.08-1.55) | 0.17    | 2.32 (0.51-10.54) | 0.28    | 0.56 (0.16-1.92)         | 0.36    |
| GG              | 1.00 (reference)             |         |                  |         |                   |         |                          |         |
| T               | 1.37 (0.73-2.57)             | 0.33    | 0.46 (0.24-0.90) | 0.02*   | 2.22 (1.02-4.82)  | 0.04*   | 1.02 (0.57-1.81)         | 0.95    |
| G               | 1.00 (reference)             |         |                  |         |                   |         |                          |         |
| Dominant model  |                              |         |                  |         |                   |         |                          |         |
| TT + GT         | 1.60 (0.55-4.65)             | 0.39    | 0.33 (0.12-0.96) | 0.04*   | 2.54 (0.70-9.16)  | 0.16    | 0.82 (0.33-2.03)         | 0.66    |
| GG              | 1.00 (reference)             |         |                  |         |                   |         |                          |         |
| Recessive model |                              |         |                  |         |                   |         |                          |         |
| GG + GT         | 0.78 (0.35-1.76)             | 0.55    | 1.97 (0.74-5.26) | 0.18    | 0.62 (0.26-1.48)  | 0.28    | 0.84 (0.39-1.80)         | 0.66    |
| TT              | 1.00 (reference)             |         |                  |         |                   |         |                          |         |
| <b>Model 2</b>  |                              |         |                  |         |                   |         |                          |         |
| TT              | 1.62 (0.49-5.34)             | 0.43    | 0.35 (0.10-1.22) | 0.10    | 3.04 (0.77-12.06) | 0.11    | 1.06 (0.39-2.87)         | 0.91    |
| GT              | 1.46 (0.35-6.16)             | 0.61    | 0.29 (0.06-1.44) | 0.13    | 2.64 (0.54-13.02) | 0.23    | 0.49 (0.14-1.79)         | 0.28    |
| GG              | 1.00 (reference)             |         |                  |         |                   |         |                          |         |
| T               | 1.25 (0.63-2.52)             | 0.52    | 0.47 (0.23-0.98) | 0.04*   | 2.25 (0.98-5.17)  | 0.06    | 1.16 (0.63-2.13)         | 0.63    |
| G               | 1.00 (reference)             |         |                  |         |                   |         |                          |         |
| Dominant model  |                              |         |                  |         |                   |         |                          |         |
| TT + GT         | 1.58 (0.49-5.04)             | 0.44    | 0.33 (0.10-1.08) | 0.07    | 2.94 (0.76-11.34) | 0.12    | 0.88 (0.34-2.29)         | 0.79    |
| GG              | 1.00 (reference)             |         |                  |         |                   |         |                          |         |
| Recessive model |                              |         |                  |         |                   |         |                          |         |
| GG + GT         | 0.75 (0.30-1.86)             | 0.54    | 1.64 (0.56-4.80) | 0.37    | 0.57 (0.22-1.45)  | 0.24    | 0.68 (0.30-1.54)         | 0.35    |
| TT              | 1.00 (reference)             |         |                  |         |                   |         |                          |         |

\*p&lt;0.05. Model 1: crude odds ratio; model 2: adjusted odds ratio for age, gender, BMI, waist circumferences, blood pressure, HbA1c level, fasting plasma glucose level, and smoking status. GG: wildtype homozygote; GT: heterozygote; TT: mutant homozygote.

The most exciting finding was that the mutant allele of rs2075604 (T allele) had a protective factor against low HDL-c. This intron variant may have a beneficial effect related to HDL-c. It was confirmed that low HDL-c levels could increase ASCVD risk (Kjeldsen et al., 2022; Li et al., 2020). Therefore, this result indicated that ASCVD risk was reduced among patients with a mutant allele of rs2075604.

In addition, this study found an abnormal correlation related to HbA1c and LDL-c. It was obvious that uncontrolled HbA1c could worsen LDL-c in theoretically from clinical data (Hussain et al., 2017; Nair et al., 2020). Previous studies also could not detect HbA1c as an LDL-c predictor (Alzahrani et al., 2019). The irrelevant result might be caused by the high variance factors contributing to the lipid profile abnormality, not only controlled HbA1c. However, the irrelevant correlation between HbA1c and LDL-c did not affect the association of *STK11* rs2075604. After considering the HbA1c level, there is no significant association between *STK11* rs2075604 and high LDL-c.

Interestingly, the T allele, mutant without adjusting with any confounding factors, increases the risk of high LDL-c. The significant association was deleted in model 2. It could be meant that high LDL-c was more affected by other clinical data compared to *STK11* rs2075604. Previous studies confirmed that uncontrolled blood glucose and smoking highly affected LDL-c (Jain and Ducatman, 2018; Panjeta et al., 2018). Notably, diet is another factor contributing to lipid profiles (Schoeneck and Iggman, 2021).

The major limitations of this study are (1) cross-sectional study design; therefore, the causation could not be determined between exposure of mutant and lipid profiles abnormality, (2) confounding factors, including diet, physical activities, and adherence, could not be identified, thus contributing bias in these finding, (3) sample size is acceptable, and this research recruited from 10 primary health cares; however it remains not representative in Indonesian race.

## CONCLUSION

This recent study indicated that *STK11* rs2075604 is a new perspective related to one of the protectant factors for low HDL-c among newly diagnosed T2DM. T allele as a mutant of rs2075604 has the protective role to low HDL-c risk among newly diagnosed T2DM patients in Indonesia. *STK11* rs2075604 could be a better strategy to emphasize poor HDL-c level management. A healthcare professional could utilize this finding to prioritize patients to reduce ASCVD. Due to the mutant allele only affecting LDL-c in the non-adjusted model, further study is recom-

mended to confirm and validate the effect of rs2075604 on LDL-c.

## CONFLICT OF INTEREST

The authors declare no conflicts of interest.

## ACKNOWLEDGMENTS

Special thanks to all the participants for their cooperation and the involved health practitioners in public health care in Sleman Districts. This study was funded by Institution of Research and Community Services Sanata Dharma University (No. 007 Penel./LPPM-USD/II/2022).

## REFERENCES

- Alzahrani SH, Baig M, Aashi MM, Al-shaibi FK, Alqarni DA, Bakhamees WH (2019) Association between glycated hemoglobin (HbA1c) and the lipid profile in patients with type 2 diabetes mellitus at a tertiary care hospital: A retrospective study. *Diabetes Metab Syndr Obes* 12: 1639–1644. <https://doi.org/10.2147/DMSO.S222271>
- American Diabetes Association (2020) Standards of medical care in diabetes. *Diabetes Care* 43: S14–S31. <https://doi.org/10.2337/dc20-S002>
- Cai R, Han J, Sun J, Huang R, Tian S, Shen Y, Wang S (2017) Effects of ABCA1 R219K polymorphism and serum lipid profiles on mild cognitive impairment in type 2 diabetes mellitus. *Front Aging Neurosci* 9: 257. <https://doi.org/10.3389/fnagi.2017.00257>
- Dawed AY, Zhou K, Pearson ER (2016) Pharmacogenetics in type 2 diabetes: influence on response to oral hypoglycemic agents. *Pharmacogenomics Pers Med* 9: 17–29. <https://doi.org/10.2147/PGPM.S84854>
- Dietrich S, Jacobs S, Zheng JS, Meidtnier K, Schwingshackl L, Schulze MB (2019) Gene-lifestyle interaction on risk of type 2 diabetes: A systematic review. *Obes Rev* 20: 1557–1571. <https://doi.org/10.1111/obr.12921>
- Dinas KKS (2020) Profil Kesehatan Kabupaten Sleman Tahun 2020. In: Dinas Kesehatan Sleman (Issue 0274).
- Freeman VS (2014) Glucose and hemoglobin A1c. *Lab Med* 45: e21–e24. <https://doi.org/10.1309/LMNSU432YJWCWZKX>
- Friedewald WT, Levy RI, Fredrickson DS (1972) Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. *Clin Chem* 18: 499–502. <https://doi.org/10.1093/clinchem/18.6.499>
- Hussain A, Ali I, Ijaz M, Rahim A (2017) Correlation between hemoglobin A1c and serum lipid profile in Afghani patients with type 2 diabetes: hemoglobin A1c prognosticates dyslipidemia. *Ther Adv Endocrinol Metab* 8: 51–57. <https://doi.org/10.1177/2042018817692296>
- Ikhsan YK, Soelistijo SA, Putranto JNE (2022) Profile of cardiovascular disease risk in type 2 diabetes mellitus patients receiving statin therapy: A cross-sectional study. *Ann Med Surg* 75: 103368. <https://doi.org/10.1016/j.amsu.2022.103368>
- Jain RB, Ducatman A (2018) Associations between smoking and lipid/lipoprotein concentrations among US adults aged ≥20 years. *J Circ Biomark* 7: 1849454418779310. <https://doi.org/10.1177/1849454418779310>
- Jayakumari C, Jabbar PK, Soumya S, Jayakumar RV, Das DV, Girivishnu G, Gopi A, Gomez R, Sreenath R, Nair A (2020) Lipid profile in Indian patients with type 2 diabetes: The scope for atherosclerotic cardiovascular disease risk reduction.

- Diabetes Spectr 33: 299–306. <https://doi.org/10.2337/ds19-0046>
- Jeon SM (2016) Regulation and function of AMPK in physiology and diseases. *Exp Mol Med* 48: 245–258. <https://doi.org/10.1038/emm.2016.81>
- Just PA, Charawi S, Denis RGP, Savall M, Traore M, Foretz M, Bastu S, Magassa S, Senni N, Sohler P, Wursmer M, Vasseur-Cognet M, Schmitt A, Le Gall M, Leduc M, Guillonneau F, De Bandt JP, Mayeux P, Romagnolo B, Luquet S, Bossard P, Perret C (2020) Lkb1 suppresses amino acid-driven gluconeogenesis in the liver. *Nat Commun* 11: 6127. <https://doi.org/10.1038/s41467-020-19490-6>
- Kahena B, Afef B, Wafa F, Eya K, Rolande D, Faika BM, Jaouida A (2013) Advantage of HbA1c assay by HPLC D-10 versus Cobas Integra 400 in a population carrier for HbS and HbC. *Clin Lab* 58: 821–828. <https://doi.org/10.7754/clin.lab.2012.110717>
- Kementerian Kesehatan RI (2020) Infodatin tetap produktif, cegah, dan atasi Diabetes Melitus 2020. In : Pusat Data dan Informasi Kementerian Kesehatan RI. Jakarta: Kementerian Kesehatan RI, pp. 1–10.
- Keshavarz P, Inoue H, Nakamura N, Yoshikawa T, Tanahashi T, Itakura M (2008) Single nucleotide polymorphisms in genes encoding LKB1 (STK11), TORC2 (CRTC2) and AMPK  $\alpha$ 2-subunit (PRKAA2) and risk of type 2 diabetes. *Mol Genet Metab* 93: 200–209. <https://doi.org/10.1016/j.ymgme.2007.08.125>
- Kjeldsen EW, Thomassen JQ, Frikke-Schmidt R (2022) HDL cholesterol concentrations and risk of atherosclerotic cardiovascular disease – Insights from randomized clinical trials and human genetics. *Biochim Biophys Acta* 1867: 159063. <https://doi.org/10.1016/j.bbali.2021.159063>
- Kumari A, Sedehizadeh S, Brook JD, Kozlowski P, Wojciechowska M (2022) Differential fates of introns in gene expression due to global alternative splicing. *Hum Genet* 141: 31–47. <https://doi.org/10.1007/s00439-021-02409-6>
- Li C, Yang Y, Liu X, Li Z, Liu H, Tan Q (2020) Glucose metabolism-related gene polymorphisms as the risk predictors of type 2 diabetes. *Diabetol Metab Syndr* 12: 97. <https://doi.org/10.1186/s13098-020-00604-5>
- Li Q, Li C, Li H, Zeng L, Kang Z, Mao Y, Tang X, Zheng P, He L, Luo F, Li Z (2017) STK11 rs2075604 Polymorphism is associated with metformin efficacy in Chinese type 2 diabetes mellitus. *Int J Endocrinol* 2017: 3402808. <https://doi.org/10.1155/2017/3402808>
- López-Bermejo A, Díaz M, Morán E, De Zegher F, Ibáñez L (2010) A single nucleotide polymorphism in STK11 influences insulin sensitivity and metformin efficacy in hyperinsulinemic girls with androgen excess. *Diabetes Care* 33: 1544–1548. <https://doi.org/10.2337/dc09-1750>
- Ma CX, Ma XN, Guan CH, Li YD, Mauricio D, Fu SB (2022) Cardiovascular disease in type 2 diabetes mellitus: progress toward personalized management. *Cardiovasc Diabetol* 21: 74. <https://doi.org/10.1186/s12933-022-01516-6>
- Moustapha D, Oumou BNK, Matar KP, Ngor SR, Malick NEH, Fatou GT, Marieme TN, Ange TSBH, Fatou CGN, Dominique D, Rokhaya ND, Maimouna NM, Aynina C, Amadou DP, Philomène LS, Madieye GP (2020) Evaluation of lipid profile and atherogenic index of plasma in patients with type 2 diabetes (AIP = log TG/HDL-c). *Asian J Biochem Genet Mol Biol* 5: 24–30. <https://doi.org/10.9734/ajbgbmb/2020/v5i330132>
- Nair DR, Satheesh K, Raghavan A, Nanditha A, Vinitha R, Susairaj P, Snehalatha C, Ramachandran A (2020) Trend in the clinical profile of type 2 diabetes in India - Study from a diabetes care centre in South India. *Diabetes Metab Syndr* 14: 1851–1857. <https://doi.org/10.1016/j.dsx.2020.09.018>
- <https://jppres.com>
- NCBI (2022) rs2075604 RefSNP Report - dbSNP - NCBI. <https://www.ncbi.nlm.nih.gov/snp/rs2075604>
- Nicchio IG, Cirelli T, Nepomuceno R, Hidalgo MAR, Rossa C, Cirelli JA, Orrico SRP, Barros SP, Theodoro LH, Scarel-Caminaga RM (2021) Polymorphisms in genes of lipid metabolism are associated with type 2 diabetes mellitus and periodontitis, as comorbidities, and with the subjects' periodontal, glycemic, and lipid profiles. *J Diabetes Res* 2021: 1049307. <https://doi.org/10.1155/2021/1049307>
- Panjeta E, Jadrić R, Panjeta M, Ćorić J, Dervišević A (2018) Correlation of serum lipid profile and glycemic control parameters in patients with type 2 diabetes mellitus. *J Health Sci* 8: 110–116. <https://doi.org/10.17532/jhsci.2018.488>
- Rose AB (2018) Introns as gene regulators: A brick on the accelerator. *Front Genet* 9: 672. <https://doi.org/10.3389/fgene.2018.00672>
- Rusdiana R, Widjaja SS, Savira M (2020) The relation between lipid profile and glycemic control in type 2 diabetes mellitus patients in North Sumatera, Indonesia. *Open Access Maced J Med Sci* 8: 887–891. <https://doi.org/10.3889/oamjms.2020.5174>
- Schoeneck M, Iggman D (2021) The effects of foods on LDL cholesterol levels: A systematic review of the accumulated evidence from systematic reviews and meta-analyses of randomized controlled trials. *Nutr Metab Cardiovasc Dis* 31: 1325–1338. <https://doi.org/10.1016/j.numecd.2020.12.032>
- Sokolova LK, Pushkarev VM, Belchina YB, Pushkarev VV, Vatseba TS, Tronko ND (2019) Association of 5'AMP-activated protein kinase activity with disease duration and HbA1c content in leukocytes in diabetic patients. *Int J Endocrinol (Ukraine)* 15: 23–26. <https://doi.org/10.22141/2224-0721.15.1.2019.158688>
- Suhadi R, Virginia DM, Setiawan CH (2017) Association of lipid profiles with 10-year atherosclerotic cardiovascular disease risk: Study among subjects in sleman district of Yogyakarta Indonesia. *Asian J Pharm Clin Res* 10: 166–170. <https://doi.org/10.22159/AJPCR.2017.V10I12.20675>
- Sun H, Saeedi P, Karuranga S, Pinkepank M, Ogurtsova K, Duncan BB, Stein C, Basit A, Chan JCN, Mbanya JC, Pavkov ME, Ramachandran A, Wild SH, James S, Herman WH, Zhang P, Bommer C, Kuo S, Boyko EJ, Magliano DJ (2022) IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. *Diabetes Res Clin Pract* 183: 109119. <https://doi.org/10.1016/j.diabres.2021.109119>
- Vardarli AT, Harman E, Çetintaş VB, Kayıkcıoğlu M, Vardarli E, Zengi A, Küçükbaşlan AŞ, Eroğlu Z (2017) Polymorphisms of lipid metabolism enzyme-coding genes in patients with diabetic dyslipidemia. *Anatol J Cardiol* 17: 313–321. <https://doi.org/10.14744/AnatolJCardiol.2016.7142>
- Virginia DM, Patramurti C, Fenty, Setiawan CH, Julianus J, Hendra P, Susanto NAP (2022) Single nucleotide polymorphism in the 3' untranslated region of PRKAA2 on cardiometabolic parameters in type 2 diabetes mellitus patients who received metformin. *Ther Clin Risk Manag* 18: 349–357. <https://doi.org/10.2147/TCRM.S349900>
- Virginia DM, Wahyuningsih MSH, Nugrahaningsih DAA (2021) Association between three variants in the PRKAA2 gene, rs2796498, rs9803799, and rs2746342, with 10-year ASCVD risk on newly diagnosed T2DM in Yogyakarta, Indonesia. *Open Access Maced J Med Sci* 9: 541–547. <https://doi.org/10.3889/oamjms.2021.6213>
- Witka BZ, Oktaviani DJ, Marcellino M, Barliana MI, Abdulah R (2019) Type 2 diabetes-associated genetic polymorphisms as potential disease predictors. *Diabetes Metab Syndr Obes* 12: 2689–2706. <https://doi.org/10.2147/DMSO.S230061>
- Yamagata H, Kobayashi A, Tsunedomi R, Seki T, Kobayashi M, Hagiwara K, Chen C, Uchida S, Okada G, Fuchikami M,

Kamishikiryo T, Iga J, Numata S, Kinoshita M, Kato TA, Hashimoto R, Nagano H, Okamoto Y, Ueno S, Ohmori T, Nakagawa S (2021) Optimized protocol for the extraction of RNA and DNA from frozen whole blood sample stored in a single EDTA tube. *Sci Rep* 11: 17075. <https://doi.org/10.1038/s41598-021-96567-2>

Zhang Y, Chen J, Zeng Y, Huang D, Xu Q (2019) Involvement of AMPK activation in the inhibition of hepatic gluconeogenesis by *Ficus carica* leaf extract in diabetic mice and HepG2 cells. *Biomed Pharmacother* 109: 188–194. <https://doi.org/10.1016/j.biopha.2018.10.077>

#### AUTHOR CONTRIBUTION:

| Contribution                       | Virginia DM, | Patramurti C | Hendra P | Lorenza PNFP | Ngai FE | Anastasia N | Defi MN | Wahyuningsih MSH | Nugrahaningsih DAA |
|------------------------------------|--------------|--------------|----------|--------------|---------|-------------|---------|------------------|--------------------|
| Concepts or ideas                  | x            | x            | x        |              |         |             | x       | x                |                    |
| Design                             | x            | x            | x        |              |         |             | x       |                  |                    |
| Definition of intellectual content | x            | x            |          |              |         |             |         |                  |                    |
| Literature search                  | x            | x            | x        |              |         |             |         |                  |                    |
| Experimental studies               | x            |              |          | x            | x       | x           | x       |                  |                    |
| Data acquisition                   | x            |              |          | x            | x       | x           | x       |                  |                    |
| Data analysis                      |              |              | x        | x            | x       | x           | x       |                  |                    |
| Statistical analysis               | x            |              |          |              |         |             |         | x                | x                  |
| Manuscript preparation             | x            |              |          | x            | x       | x           | x       |                  |                    |
| Manuscript editing                 |              | x            | x        |              |         |             |         | x                | x                  |
| Manuscript review                  | x            | x            | x        | x            | x       | x           | x       | x                | x                  |

**Citation Format:** Virginia DM, Patramurti C, Hendra P, Lorenza PNFP, Ngai FE, Anastasia N, Defi MN, Wahyuningsih MSH, Nugrahaningsih DAA (2023) The mutant of rs2075604 in *STK11* improves HDL-c levels among newly diagnosed type 2 diabetes mellitus patients. *J Pharm Pharmacogn Res* 11(2): 255–262. [https://doi.org/10.56499/jppres22.1541\\_11.2.255](https://doi.org/10.56499/jppres22.1541_11.2.255)

**Publisher's Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

**Open Access:** This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<http://creativecommons.org/licenses/by/4.0/>), which permits use, duplication, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if changes were made.